BioStem Technologies (OTCMKTS:BSEM) Announces Earnings Results, Beats Expectations By $0.01 EPS

BioStem Technologies (OTCMKTS:BSEM) released its earnings results on Tuesday. The company reported 0.32 EPS for the quarter, beating the consensus estimate of 0.31 by 0.01, Zacks reports. The firm had revenue of 82.56 million during the quarter, compared to the consensus estimate of 78.22 million.

BioStem Technologies Price Performance

OTCMKTS BSEM traded up 0.26 during trading on Wednesday, reaching 24.98. 170,900 shares of the company’s stock were exchanged, compared to its average volume of 32,205. The business has a 50 day moving average price of 12.75 and a 200-day moving average price of 10.44. BioStem Technologies has a fifty-two week low of 2.34 and a fifty-two week high of 28.26. The stock has a market capitalization of $415.17 million, a P/E ratio of 64.05 and a beta of -0.36.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.